Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 15th November 2021

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Teams.
The minutes and summary notes of the Medicines Group Meeting held on 12th July 2021 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- **Estradiol Metered-dose Transdermal 1.53mg Spray (Lenzetto®)**

Requested by Gynaecology to be added to the CWFT formulary, to be prescribed after risk-benefit analysis of hormone replacement therapy (HRT) in post-menopausal women experiencing oestrogen deficiency symptoms. Lenzetto® is a transdermal spray which can be used 1st/2nd or 3rd line and offers an alternative delivery method with additional convenience in contrast to other formulations such as patches, gels and tablets. Spray is an ideal formulation for patients who wish to be prescribed a transdermal formulation but prefer not to use a gel or patches which are sometimes not suitable due to lifestyle. This will require application to the NWLIF to permit ongoing prescribing by GPs once initiated in secondary care.
Outcome: Approved for addition to the formulary

- **Calcium Acetate (Phosex®) 1g Tablets**

Requested by Renal Medicine to be added to the CWFT formulary, to be prescribed for the management of hyperphosphataemia in Chronic Kidney Disease (CKD) Stages 4 or 5. In line with NICE Guidance NG203 (August 2021) Phosex® should be considered 1st line in place of therapy for the management of hyperphosphataemia in patients with CKD Stage 4 or 5 and duration of treatment would anticipated to be lifelong. This is an off-label use of Phosex® which is licensed only for patients undergoing dialysis. Due to limited evidence for adults not on dialysis, NICE extrapolated their outcome from the evidence available for adults with Stage 5 CKD on dialysis so they could make recommendations or the other groups. NICE concluded that Calcium Acetate as first-line treatment provided the best balance in terms of benefits, harms and cost.
It was agreed that wider discussion would need to take place before adding this to NWLIF, however based on low patient numbers, low cost and NICE recommendation, the panel agreed to add this to the formulary.
Outcome: Approved for addition to the formulary

Ex-panel

- **Nil**

Removals

- **Diazepam rectal Tubes (RecTubes)®2.5mg**

Discontinued by the manufacturers
Outcome: Approved for removal from the formulary

- **Azathoprine 50mg Injection**

Discontinued by the manufacturers
Outcome: Approved for removal from the formulary

NICE Approved drug applications

- Nil

Pharmacoeconomic Board requests

- For noting IVIG for Anti-Yo Paraneoplastic Cerebellar Syndrome

Approved by the Pharmacoeconomic Board on 24/08/2021
Outcome: Noted

- Eculizumab for Refractory autoimmune haemolytic anaemia

Approved by the Pharmacoeconomic Board on 27/08/2021
Outcome: Noted

- Infliximab for Tuberculosis

Approved by the Pharmacoeconomic Board on 13/09/2021
Outcome: Noted

- Tocilizumab for IL-6 Driven auto-inflammatory syndrome

Approved by the Pharmacoeconomic Board on 01/10/2021
Outcome: Noted

- Sacituzumab for Triple Negative Breast Cancer

Approved by the Pharmacoeconomic Board on 12/10/2021
Outcome: Noted

4.2 Trust Medicines Policy

- **TMP Update - Progress report - November 2021**

TMP Update - Progress report for November 2021.
Outcome: Noted

- **TMP - Section 2: Prescribing of medicines**

Routine review and update
Updated in line with Cerner EPMA
Outcome: Approved

- **TMP - Section 9: Patient's own medicines**

Scheduled review and update

- Updated in line with Cerner EPMA
- Removal of the need to document the quantity of PODs available on Cerner as this currently not a facility that is available on Cerner EPMA.
- Change to using Cerner EPMA to document patient's consent for use and destruction of PODs removing the need for paper forms.
- Appendices removed

Outcome: Approved

- **TMP - Section 11: Medicine recalls**

Routine review and update.

- Update of policy/procedure titles
- Addition of company initiated recalls
- Update to clarify that it is the responsibly of the Pharmacy procurement team to report adverse events/defects relating to medicines externally.
- Addition of a section relating to documentation archiving

Outcome: Approved

- **TMP - Section 29: Policy for the provision of additional private care**

Routine review and update including review by the Commercial Manager & Acting General Manager - Private Care CWFT
Outcome: Approved

- **TMP - Section 32: In-patient self-administration of medicines**

Routine review and update
- Updated in line with Cerner EPMA
- Removal of LWMH as an exclusion to self-administration where the patient is likely to self-administer following discharge
- Statement added regarding supported administration by a patient's partner/carer.
- Addition of the use of the Medication Passport.

Outcome: Approved

- **Updates to the Adult IV Administration Guide**

Addition of new monographs for
- Andexanet
- Cefidericol
- Sarilumab

Update to the infusion instructions for Magnesium Sulphate in **pregnancy** for the prevention of seizures in the foetus (foetal neuro-protection) associated with pre-eclampsia following an administration error in Maternity.
Outcome: Approved

4.3 Medicines Optimisation

- **Guidelines for the use of Ketamine in Acute Pain Management in Adults**

Guideline written to support the appropriate and safe use of Ketamine in Acute Pain Management in the Trust
Outcome: Approved

- **Guideline for Pharmacy and medical staff managing patients on clozapine**

Guideline written to support the safe management of patients admitted to the Trust who are receiving Clozapine.
Outcome: Approved

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

8 appraisals published in July 2021
3 appraisals published in August 2021
9 appraisals published in September 2021
8 appraisals published in October 2021

TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA712
Numbers likely to treat at CWH site: 3 patients per year
Numbers likely to treat at WMUH site: 0 patient per year; condition not treated at WMUH site

TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA713
Numbers likely to treat at CWH site: 3-5 patients per year
Numbers likely to treat at WMUH site: 0 patient per year; condition not treated at WMUH site
TA714 - Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Terminated appraisal)

Formulary status / Action
Nil action - Terminated appraisal

TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA715
Numbers likely to treat at CWH site: 30-50 patients already under our care plus additional 30 patients next year
Numbers likely to treat at WMUH site: 50 patients per year

TA716 - Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Formulary status / Action
Currently included on the CWFT formulary
Numbers likely to treat at both sites: 0 patients per year; condition not treated at CWH and WMUH site

TA717 - Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (Terminated appraisal)
Formulary status / Action
Nil action - Terminated appraisal

TA718 - Ixekizumab for treating axial spondyloarthritis
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA718
Numbers likely to treat at CWH site: 10-15 patients per year
Numbers likely to treat at WMUH site: 10 patients per year

TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA719
Numbers likely to treat at CWH site: 10-15 patients per year
Numbers likely to treat at WMUH site: 20 patients per year

TA720 - Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
Formulary status / Action
Nil action - Not applicable - Condition not treated at CWH and WMUH site

TA721 - Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
Formulary status / Action
Nil action - Not recommended

TA722 - Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
Formulary status / Action
Nil action - Not applicable - Condition not treated at CWH and WMUH site

TA723 - Bimekizumab for treating moderate to severe plaque psoriasis
Formulary status / Action
Currently not included on the CWFT formulary
Action: Add to the formulary following receipt of an application form from Dermatology Team by 01/12/2021
Numbers likely to treat at CWH site: 5 patients per year
Numbers likely to treat at WMUH site: 15 patients per year

TA724 - Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
Formulary status / Action
Nil action - Not recommended

TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA725
Numbers likely to treat at CWH site: 0 patients per year
Numbers likely to treat at WMUH site: 2 patient per year

TA726 - Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Formulary status / Action
Nil - Terminated appraisal
No action

TA727 - Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma
Formulary status / Action
Nil action - Terminated appraisal

TA728 - Midostaurin for treating advanced systemic mastocytosis
Formulary status / Action
Nil action - Condition is not treated at CWH and WMUH site

TA729 - Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
Formulary status / Action
Nil action - Condition not treated at CWH and WMUH site

TA730 - Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours
Formulary status / Action
Nil action - Terminated appraisal

TA731 - Vericiguat for treating chronic heart failure with reduced ejection fraction
Formulary status / Action
Nil - Terminated appraisal
No action

TA732 - Baloxavir marboxil for treating acute uncomplicated influenza
Formulary status / Action
Nil action - Terminated appraisal

TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
Formulary status / Action
Currently not included on the CWFT formulary
Action: Add to the formulary following receipt of an application form from Cardiology/ Endocrine Team by 06/01/2022
Update: Medicine Team have been advised to await approval pending NWLIF decision regarding treatment and commissioning pathway

TA734 - Secukinumab for treating moderate to severe plaque psoriasis in children and young people
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA734
Numbers likely to treat at CWH site: 5 patients per year
Numbers likely to treat at WMUH site: 0 patients per year

TA735 - Tofacitinib for treating juvenile idiopathic arthritis
Formulary status / Action
Currently included on the CWFT formulary
Action: Confirm commissioning status for CWFT

TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Formulary status / Action
Nil action - Condition not treated at CWH and WMUH site
CWFT NOT commissioned

TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
Formulary status / Action
Nil action - Condition not treated at CWH and WMUH site
CWFT NOT commissioned

TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema
Formulary status / Action
Nil action - Condition not treated at CWH and WMUH site
CWFT NOT commissioned

TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
Formulary status / Action
Currently included on the CWFT formulary
Action: Update for use in line with NICE TA739
Numbers likely to treat at CWH site: 1-2 patients per year
Numbers likely to treat at WMUH site: 0 patients per year

b) NICE Highly Specialised Technologies published since last meeting

HST15 - Onasemnogene abeparvovec for treating spinal muscular atrophy
Formulary status / Action
Nil action - Not applicable - CWFT not commissioned

<u>4.5 IVIG requests</u>

- **IVIG Issues for June 2021 - CW Site**

Outcome: Noted

- **IVIG Issues for June 2021 - WMUH Site**

Outcome: Noted

- **IVIG Issues for July 2021 - CWH Site**

Outcome: Noted

- **IVIG Issues for July 2021 - WMUH Site**

Outcome: Noted

- **IVIG Issues for August 2021 - CWH Site (Tabelled)**

Outcome: Noted

- **IVIG Issues for August 2021 - WMUH Site (Tabelled)**

Outcome: Noted

- **IVIG Issues for September 2021 - CWH Site (Tablelled)**

Outcome: Noted

- **IVIG Issues for September 2021 - WMUH Site (Tabelled)**

Outcome: Noted

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q1 2021/22**

Quarterly Controlled Drug Summary Report for Q1 2021/22
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q1 2021/22**

Quarterly CD Accountable Officer Report for Q1 2021/22
Outcome: Noted

- **Medication Safety Bulletin - Medicines management and storage**

Medication safety Bulletin relating to Medicines management and storage
Outcome: Noted

- **Medication Safety Bulletin - MHRA Yellow card reporting**

Medication safety Bulletin relating to MHRA Yellow card reporting
Outcome: Noted

- **Medication Safety Bulletin - Medication safety in NICU**

Medication safety Bulletin relating to Medication safety in NICU
Outcome: Noted

- **Medication Safety Bulletin - Concomitant prescribing and administration of paracetamol**

Medication safety Bulletin relating to Concomitant prescribing and administration of paracetamol
Outcome: Noted

- **Trust Medicines Group and Trust Medication Safety Group report for the Patient Safety Group - August 2021**

Trust Medicines Group and Trust Medication Safety Group report for the Patient Safety Group noted in August 2021
Outcome: Noted

- **Trust Medicines Group - Terms of Reference**

Terms of Reference for Trust Medicines Group - Draft for comment
Updates include
- HIV/GUM representative
- Removal of IVIg Approval Panel
- Addition of Pharmacy IVIg Lead
- Addition of Medicines Optimisation Group

Outcome: Approved

- **MHRA Drug Safety Update - July 2021**

MHRA update for July 2020
Outcome: Noted

- **MHRA Drug Safety Update - August 2021**

MHRA update for August 2020
Outcome: Noted

- **MHRA Drug Safety Update - September 2021**

MHRA update for September 2021
Outcome: Noted

- **MHRA Drug Safety Update - October 2021**

MHRA update for October 2021
Outcome: Noted

4.7 Meeting minutes for noting

- **Nil**

5. Any other business

- **Nil**

6. Date of next meeting

Next meeting
Date: 13th December 2021 at 8-9am
Time: 8am-9am
Location: via Teams